Also trades as: HUMAW (NASDAQ) · $vol 0M
HUMA NASDAQ
Humacyte, Inc.
1W: +2.0%
1M: +44.7%
3M: -9.7%
YTD: +4.6%
1Y: -59.0%
3Y: -73.8%
5Y: -89.7%
$1.05
+0.03 (+2.94%)
Weekly Expected Move ±19.4%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$2M
+0.0% ▲
5Y CAGR: +6.4%
Gross Profit
-$15M
-108.7% ▼
Operating Income
-$107M
+6.1% ▲
Net Income
-$41M
+72.5% ▲
EPS (Diluted)
$-0.26
+79.4% ▲
EBITDA
-$100M
+24.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1M | $2M | $0 | $0 | $2M |
| YoY Growth | -15.3% | +23.9% | -100.0% | +0.0% | +0.0% |
| Cost of Revenue | $61M | $8M | $77M | $7M | $17M |
| Gross Profit | -$60M | -$7M | -$77M | -$7M | -$15M |
| Gross Margin | -4756.8% | -427.5% | — | — | -736.5% |
| R&D Expenses | $61M | $63M | $77M | $89M | $69M |
| SG&A Expenses | $21M | $23M | $20M | $26M | $31M |
| Operating Expenses | $21M | $78M | $23M | $107M | $92M |
| Operating Income | -$81M | -$85M | -$100M | -$114M | -$107M |
| Operating Margin | -6429.8% | -5404.3% | — | — | -5271.7% |
| Interest Expense | $4M | $6M | $7M | $9M | $11M |
| Income Before Tax | -$26M | -$12M | -$111M | -$149M | -$41M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$26M | -$12M | -$111M | -$149M | -$41M |
| Net Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| EPS (Diluted) | $-0.66 | $-0.12 | $-1.07 | $-1.26 | $-0.26 |
| EBITDA | -$73M | -$76M | -$96M | -$132M | -$100M |
| Shares Outstanding | 40M | 103M | 103M | 118M | 158M |